An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 6, 2012, Pages 1477-1486

  Asahina, Hajime ^a   Tamura, Yosuke ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Seki, Yoshitaka ^a   Shibata, Takashi ^a   Goto, Yasushi ^a   Tanioka, Maki ^a   Yamada, Yasuhide ^a   Coates, Andrew ^b   Chiu, Yi Lin ^b   Li, Xiaohui ^b   Pradhan, Rajendra ^b   Ansell, Peter J ^b   McKeegan, Evelyn M ^b   McKee, Mark D ^b   Carlson, Dawn M ^b   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Angiogenesis; Japanese; Linifanib (ABT 869); PDGFR; Solid tumors; VEGFR

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; LINIFANIB; MAGNESIUM; THYROTROPIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTRITIS; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; JAPANESE; LEUKOPENIA; LUNG CANCER; LYMPHOCYTE COUNT; MAGNESIUM BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; T WAVE; T WAVE INVERSION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYMUS CANCER; THYROTROPIN BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; HUMANS; INDAZOLES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS; PHENYLUREA COMPOUNDS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84863796413     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1846-6     Document Type: Article

References (36)

1. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380
2. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653-660
3. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165
4. Cook KM, Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60:222-243
5. Feng X, Ofstad W, Hawkins D (2010) Antiangiogenesis therapy: a new strategy for cancer treatment. US Pharm 35:4-9
6. Perona R (2006) Cell signalling: growth factors and tyrosine kinase receptors. Clin Transl Oncol 8:77-82
7. Homsi J, Daud A (2007) Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 14:285-294
8. Erber R, Thurnher A, Katsen A, Groth G, Kerger H, Hammes H, Menger M, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338-340
9. Dai Y, Hartandi K, Ji Z, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, Harris CM, Hickman D, Guo J, Li J, Marcotte PA, Marsh KC, Moskey MD, Martin RL, Olson AM, Osterling DJ, Pease LJ, Soni NB, Stewart KD, Stoll VS, Tapang P, Reuter DR, Davidsen SK, Michaelides MR (2007) Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)- N'-(2-fluoro-5-methylphenyl) urea (ABT-869), a 3-aminoindazole- based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 50:1584-1597
10. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, Wang B, Bukofzer GT, Wang YC, Stavropoulos JA, Hartandi K, Niquette AL, Soni N, Johnson EF, McCall JO, Bouska JJ, Luo Y, Donawho CK, Dai Y, Marcotte PA, Glaser KB, Michaelides MR, Davidsen SK (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5:995-1006
11. Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, Davidsen SK, Glaser KB (2006) Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 5:1007-1013
12. Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, Michaelides MR, Davidsen SK, Priceman SJ, Chang JC, Rhodes K, Shah N, Moore TB, Sakamoto KM, Glaser KB (2007) ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 109:3400-3408
13. Zhou N, Moradei O, Raeppel S, Leit S, Frechette S, Gaudette F, Paquin I, Bernstein N, Bouchain G, Vaisburg A, Jin Z, Gillespie J, Wang J, Fournel M, Yan PT, Trachy-Bourget MC, Kalita A, Lu A, Rahil J, MacLeod AR, Li Z, Besterman JM, Delorme D (2008) Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2- ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 51:4072-4075
14. Wong C-I, Koh T-S, Soo R, Hartono S, Thng C-H, McKeegan E, Yong W-P, Chen C-S, Lee S-C, Wong J, Lim R, Sukri N, Lim S-E, Ong A-B, Steinberg J, Gupta N, Pradhan R, Humerickhouse R, Goh B-C (2009) Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 27:4718-4726
15. Tan E-H, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC-H, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA (2011) Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thor Oncol 6:1418-1425
16. Toh HC, Chen PJ, Carr B, Knox JJ, Gill S, Qian J, Qin Q, Ricker JL, Carlson DM, Yong WP (2010) Linifanib treatment in advanced hepatocellular carcinoma (HCC) patients: a phase 2 trial. Hepatology 52(Suppl 1):1166A (abstract 1777)
17. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD (2011) Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 47:2706-2714
18. NCI (2006) Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer.gov
19. National Institutes of Health: An open label, phase 1 study evaluating pharmacokinetics, safety and tolerability of ABT-869 in subjects with solid tumors. Protocol: (NCT00718380). http://clinicaltrials.gov/
20. Therasse P, Arbuck SG, Eisenhauer EA (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
21. Fujisaka Y, Yamada Y, Yamamoto N, Shimizu T, Fujiwara Y, Yamada K, Tamura T, Watanabe H, Sun Y-N, Bass MB, Seki M (2010) Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 66:935-943
22. Minami H, Kawada K, Ebi H, Kitagawa K, Kim Y-I, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K (2008) Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99:1492-1498
23. Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, Minami H (2010) Effect of axitinib (AG- 013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 101:963-968
24. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:3045-3054
25. Rosen LS, Kurzrock R, Mulay M, Vugt AV, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun Y-N, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS (2007) Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:2369-2376
26. Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DSA, Galbraith S (2011) A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Annals Oncol 22:1413-1419
27. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz H-J, Schwartz B (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426-437
28. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474-5483
29. Yamamoto N, Tamura T, Yamamoto N, Yamada K, Yamada Y, Nokihara H, Fujiwara Y, Takahashi T, Murakami H, Boku N, Yamazaki K, Puchalski T, Shin E (2009) Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTINTM), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 64:1165-1172
30. Fiedler W, Giaccone G, Lasch P, van der Horst I, Brega N, Courtney R, Abbattista A, Shalinsky DR, Bokemeyer C, Boven E (2011) Phase I trial of SU14813 in patients with advanced solid malignancies. Annals Oncol 22:195-201
31. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Annals Oncol 16:1391-1397
32. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand J-P, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35
33. Gupta N, Yan Z, LoRusso P, Ricker J, Carlson D, Pradhan R (2009) Assessment of the effect of food on the oral bioavailability and assessment of diurnal variation in the pharmacokinetics of linifanib. Mol Cancer Ther 8; (abstract B53)
34. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338
35. Soo RA, McKeegan E, Chen CS, Thng CH, Koh TS, Laird D, Zhang K, Wong CI, Gupta N, Goh BC (2008) The effect of varying doses of ABT-869 on biomarkers of angiogenesis and their correlation with pharmacodynamic outcome J Clin Oncol 26(Suppl 20); (abstract 14535)
36. Posadas EM, Tannir NM, Wong Y, Ernstoff MS, Kollmannsberger CK, Qian J, Ansell PJ, McKeegan EM, McKee MD, Ricker JL, Carlson DM, Michaelson MD (2011) Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy. ASCO Meet Abstr 29:2543